HomeCompareHNGZY vs JNJ

HNGZY vs JNJ: Dividend Comparison 2026

HNGZY yields 0.72% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HNGZY wins by $1.65M in total portfolio value
10 years
HNGZY
HNGZY
● Live price
0.72%
Share price
$4.00
Annual div
$0.03
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.68M
Annual income
$1,324,338.59
Full HNGZY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — HNGZY vs JNJ

📍 HNGZY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHNGZYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HNGZY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HNGZY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HNGZY
Annual income on $10K today (after 15% tax)
$61.54/yr
After 10yr DRIP, annual income (after tax)
$1,125,687.80/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, HNGZY beats the other by $1,121,701.81/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HNGZY + JNJ for your $10,000?

HNGZY: 50%JNJ: 50%
100% JNJ50/50100% HNGZY
Portfolio after 10yr
$853.0K
Annual income
$664,513.99/yr
Blended yield
77.90%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

HNGZY
No analyst data
Altman Z
7.2
Piotroski
7/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HNGZY buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHNGZYJNJ
Forward yield0.72%2.13%
Annual dividend / share$0.03$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%28%
Portfolio after 10y$1.68M$30.3K
Annual income after 10y$1,324,338.59$4,689.40
Total dividends collected$1.62M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: HNGZY vs JNJ ($10,000, DRIP)

YearHNGZY PortfolioHNGZY Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$10,845$144.81$10,592$272.30+$253.00HNGZY
2$11,897$293.53$11,289$357.73+$608.00HNGZY
3$13,332$601.91$12,123$472.89+$1.2KHNGZY
4$15,526$1,260.74$13,141$629.86+$2.4KHNGZY
5$19,357$2,744.31$14,408$846.81+$4.9KHNGZY
6$27,108$6,395.29$16,021$1,151.60+$11.1KHNGZY
7$45,745$16,739.89$18,122$1,588.22+$27.6KHNGZY
8$101,749$52,802.12$20,930$2,228.20+$80.8KHNGZY
9$328,397$219,525.46$24,792$3,191.91+$303.6KHNGZY
10$1,675,724$1,324,338.59$30,274$4,689.40+$1.65MHNGZY

HNGZY vs JNJ: Complete Analysis 2026

HNGZYStock

Hangzhou Tigermed Consulting Co., Ltd. provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers regulatory submission and approval, medical translation, and good manufacturing practice (GMP) consulting services; and clinical services in the areas of medical science, early clinical and late phase development, medical monitoring, project management, patient recruitment, and quality management system. It also provides biometrics services comprising data management, biostatistics, and statistical programming; and integrated technology services, such as site management, pharmacovigilance, third party audit and training, medical imaging, clinical trial system solution, central laboratory, pre-clinical, and research hospital. Further, the company offers medical device/ in vitro diagnostics (IVD) services comprising medical device testing, regulatory submission, clinical evaluation and trials, GMP certificate, EU MDR and IVDR preparation, and value-added services; and post-marketing study, real world evidence, and vaccine clinical trial services. Hangzhou Tigermed Consulting Co., Ltd. was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.

Full HNGZY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this HNGZY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HNGZY vs SCHDHNGZY vs JEPIHNGZY vs OHNGZY vs KOHNGZY vs MAINHNGZY vs ABBVHNGZY vs MRKHNGZY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.